% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Zrnig:127881,
author = {I. Zörnig$^*$ and N. Halama$^*$ and J. Lorenzo Bermejo and
C. Ziegelmeier$^*$ and E. Dickes$^*$ and A. Migdoll$^*$ and
I. Kaiser$^*$ and T. Waterboer$^*$ and M. Pawlita$^*$ and N.
Grabe$^*$ and S. Ugurel and D. Schadendorf and C. Falk and
S. Eichmüller$^*$ and D. Jäger$^*$},
title = {{P}rognostic significance of spontaneous antibody responses
against tumor-associated antigens in malignant melanoma
patients.},
journal = {International journal of cancer},
volume = {136},
number = {1},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2017-03903},
pages = {138 - 151},
year = {2015},
abstract = {Distribution, patterns and prognostic impact of spontaneous
antibody responses against different tumor-associated
antigens (TAAs) in malignant melanoma patients are unknown
so far and were investigated in this study for the first
time in a large cohort at different stages of the disease,
identifying new prognostic biomarkers for malignant
melanoma. Serum samples from 365 melanoma patients (97 Stage
I melanoma patients, 87 Stage II, 92 Stage III and 89 Stage
IV) and 100 age and gender matched healthy control donors
were analyzed. Samples were drawn at the time of diagnosis
(Stages I-III) or at time of diagnosis of distant metastasis
(Stage IV). Applying a novel multiplex assay, humoral immune
responses against 29 TAAs were determined and the
association between response and patient survival was
investigated. Antibody responses were mainly found in
melanoma patients and all tested antigens elicited immune
responses in all disease stages. Antibody responses against
single antigens were either associated with poor prognosis
and/or shorter progression-free survival (PFS) or had no
influence. While in Stages I-III significant associations
were observed between an antibody response and overall
survival or PFS, among Stage IV patients, no significant
association was found. Multivariate analyses identified
specific humoral immune responses as prognostic factors
independently of age, chemotherapy and immunotherapy.
Antibody responses against specific TAA in Stage I-III
melanoma patients correlate with poor prognosis and/or
shorter PFS. These results may help to design clinical
studies in order to evaluate the potential of these
responses as prognostic serological biomarkers.},
keywords = {Antigens, Neoplasm (NLM Chemicals)},
cin = {D120 / D015 / F020 / G010 / G183},
ddc = {610},
cid = {I:(DE-He78)D120-20160331 / I:(DE-He78)D015-20160331 /
I:(DE-He78)F020-20160331 / I:(DE-He78)G010-20160331 /
I:(DE-He78)G183-20160331},
pnm = {314 - Tumor immunology (POF3-314)},
pid = {G:(DE-HGF)POF3-314},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:24839182},
doi = {10.1002/ijc.28980},
url = {https://inrepo02.dkfz.de/record/127881},
}